Semaglutide Use Linked to Erythromelalgia Remission
Overview
A 46-year-old woman with a 4-year history of erythromelalgia experienced complete symptom remission following initiation of semaglutide, a GLP-1 receptor agonist, used for weight management. Symptom resolution occurred rapidly, prior to significant weight loss, and was sustained over 15 months of treatment.
Background
Erythromelalgia is a rare neurovascular pain disorder characterized by episodic burning pain, erythema, and increased skin temperature, often triggered by heat or exertion. It involves microvascular dysfunction and sometimes small-fiber neuropathy. Treatment options are limited and often provide inadequate relief. GLP-1 receptor agonists, such as semaglutide, have potential anti-inflammatory and vascular effects that may influence neurovascular pain syndromes.
Data Highlights
Parameter
Baseline
Week 4
15 Months
BMI (kg/m²)
33.9
33.2
23.2
Weight loss (kg)
0
2
~30
Semaglutide dose (mg weekly)
0.25 (start)
1.0
1.0
Erythromelalgia symptoms
Present (nightly episodes)
Complete remission
Remission maintained
Key Findings
The patient had a 4-year history of erythromelalgia with nightly burning pain, erythema, and heat intolerance affecting hands and feet.
Neurologic and laboratory evaluations were largely normal; no small-fiber neuropathy was detected.
Semaglutide was initiated for weight management and titrated to 1 mg weekly.
Complete symptom remission occurred by week 4, before significant weight loss.
After 15 months, the patient lost approximately 30 kg and remained symptom-free on semaglutide.
Repeat sensory testing normalized and clinical photographs confirmed resolution of skin changes.
Clinical Implications
This case suggests that GLP-1 receptor agonists like semaglutide may provide rapid and sustained relief of erythromelalgia symptoms, potentially through pharmacologic effects on inflammation and microvascular function rather than weight loss alone. Clinicians should consider the potential role of GLP-1 receptor agonists in patients with refractory erythromelalgia, while recognizing that further controlled studies are needed to confirm efficacy and safety.
Conclusion
Semaglutide treatment was associated with complete and sustained remission of erythromelalgia in this patient, highlighting a novel therapeutic avenue warranting further investigation in neurovascular pain syndromes.
References
Laugsand et al. 2024 -- Semaglutide Use Linked to Erythromelalgia Remission, JAAD Case Reports
